Results 81 to 90 of about 26,261 (211)

Effects of the glucagon-like peptide-1 receptor agonist PEG-Loxe on diabetic osteoporosis: A mechanistic study. [PDF]

Mol Metab
Zhang L, Hu J, Huang C, Gao X, Pang D, Duan L.   +5 more
europepmc   +1 more source

Trends of Obesity in Early Adulthood and Later Adulthood Across 196 Countries and Territories, 1990–2022

Obesity, EarlyView.
ABSTRACT Objective We aimed to understand the global burden of obesity in early adulthood and later adulthood over the past three decades. Methods We analyzed obesity prevalence across 196 countries/territories from 1990 to 2022 for early adulthood (age 20–49 years) and later adulthood (age ≥ 50 years) using the Non‐Communicable Disease Risk Factor ...
Abdiwahab M. Ali, Edward Giovannucci, Jason J. Liu   +2 more
wiley   +1 more source

Pneumatosis intestinalis in a patient treated with a glucagon-like peptide-1 receptor agonist and prednisone. [PDF]

JCEM Case Rep
Sutton S, Ferguson Q, Gimpelevich R, Hemadeh O.   +3 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab   +3 more
wiley   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

The Trojan horse of off-label glucagon-like peptide-1 receptor agonist use: Protecting patients through responsible practice. [PDF]

J Int Med Res
Belančić A, Jelaković B.
europepmc   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on retinal endothelial function and oxidative stress during sepsis. [PDF]

Front Pharmacol
Böhm EW, Kouchek Zadeh J, Omran W, Arad T, Pfeiffer N, Wagner FM, Patzak A, Oelze M, Daiber A, Helmstädter J, Steven S, Gericke A.   +11 more
europepmc   +1 more source

Gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy

VIEW, EarlyView.
This graphical abstract illustrates how gut dysbiosis drives diabetic retinopathy through the gut‐retina axis, a process unfolding in three interconnected stages. First, in the gut, a decrease in beneficial bacteria and an increase in pro‐inflammatory taxa compromise the intestinal barrier, causing a “leaky gut” that allows LPS to translocate into the ...
Junyan Hu, Jingxiang Zhong
wiley   +1 more source

Depression following the initiation of glucagon-like-peptide-1 receptor agonist therapy: A multinational self-controlled case series study. [PDF]

J Intern Med
Yan VKC, Peng ZY, Wong VKC, Wong ICK, Chan EWY, Ou HT, Wan EYF.   +6 more
europepmc   +1 more source